UDCA (Ursodeoxycholic acid)

DRUG8 trials

Conditions

Diabetes Mellitus, Type 2Fatty LiverFatty Liver DiseaseFatty Liver, AlcoholicFatty Liver, NonalcoholicHepatomegalyImmune-Mediated CholestasisKidney Cancer

Early Phase 1

A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis

CompletedNCT06591455

Han YingPrimary Biliary Cholangitis (PBC)

Start: 2024-09-14End: 2025-08-18Updated: 2026-08-05

Phase 2

A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics

Enrolling by invitationNCT06591468

Han YingPrimary Biliary Cholangitis (PBC)

Start: 2024-10-30End: 2027-12-31Target: 244Updated: 2025-11-28

Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis

RecruitingNCT07378761

University Hospital, MontpellierImmune-Mediated Cholestasis

Start: 2026-06-25End: 2028-12-01Target: 94Updated: 2026-09-09

Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal Tumors

RecruitingNCT07672860

Jinling Hospital, ChinaKidney Cancer

Start: 2026-06-01End: 2027-12-01Target: 146Updated: 2026-06-29

Phase 3

Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes

NCT05416580

University of Banja LukaDiabetes Mellitus, Type 2

Start: 2022-09-12End: 2024-04-30Target: 60Updated: 2023-05-11

FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy

RecruitingNCT07296458

Xijing Hospital of Digestive DiseasesPrimary Biliary Cholangitis (PBC)

Start: 2025-12-15End: 2028-12-31Target: 132Updated: 2025-12-29

Phase 4

Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis

CompletedNCT01510860

Dr. Falk Pharma GmbHPrimary Biliary Cirrhosis

Start: 2008-11-30End: 2010-07-31Updated: 2019-05-07

Unknown Phase

Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly

RecruitingNCT07068191

Phenomen PharmaFatty Liver, Fatty Liver, Alcoholic, Fatty Liver Disease +5

Start: 2025-06-19End: 2025-08-31Target: 90Updated: 2025-07-23

Related Papers

Beneficial Effects of Ursodeoxycholic Acid on Metabolic Parameters and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Randomized Double‐Blind, Placebo‐Controlled Clinical Study

Journal of Diabetes Research2024-01-0111 citations